In patients with osteoporosis-pseudoglioma syndrome due to biallelic LRP5 variants the response to bisphosphonate treatment is usually good [52, 53], but little is known about the treatment responses in those harboring heterozygous LRP5 variants. Here, LRP5 is linked to osteoporosis.